CDXS
Codexis, Inc.
CDXS offers stronger modeled upside, but that advantage does not outweigh its weaker overall profile.
OSCR
Oscar Health, Inc.
OSCR has the edge over CDXS overall, supported by stronger fundamentals and lower modeled downside.
CDXS Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Under pressure | |
| Unavailable |
CDXS's revenue is currently healthy, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
CDXS PE Valuation
CDXS has no meaningful PE right now: it lost money over the past year.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
CDXS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Stable | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect CDXS's losses to shrink, with revenue holding steady. However, they disagree widely on these estimates.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
OSCR has the edge over CDXS on the outlook, with more favorable revenue expectations.
CDXS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.18 | +$0.57 |
| Q2 2026 | -$0.32 | +$0.50 |
| Q1 2026 | -$0.35 | +$0.63 |
| Q4 2025 | -$0.50 | +$0.39 |
| Q3 2025 | -$0.75 | +$0.13 |
| Q2 2025 | -$0.82 | +$0.27 |
| Q1 2025 | -$0.98 | -$0.04 |
| Q4 2024 | -$0.89 | +$0.23 |
CDXS is still losing money, but far less than before: $0.18 per share over the past year, against $1.20 at its worst in late 2023.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over CDXS on earnings quality, reporting a profit while its opponent remains loss making.
CDXS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $19.3M | +124% |
| Q2 2026 | $14.9M | -2.7% |
| Q1 2026 | $15.2M | +102% |
| Q4 2025 | $38.9M | +81% |
| Q3 2025 | $8.6M | -33% |
| Q2 2025 | $15.3M | +92% |
| Q1 2025 | $7.5M | -56% |
| Q4 2024 | $21.5M | -19% |
CDXS's revenue is growing: $19M last quarter, up 124% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -39% | +182 points |
| Q2 2026 | -75% | +8.6 points |
| Q1 2026 | -53% | +219 points |
| Q4 2025 | 27% | +61 points |
| Q3 2025 | -220% | -91 points |
| Q2 2025 | -84% | +201 points |
| Q1 2025 | -272% | -202 points |
| Q4 2024 | -34% | -35 points |
CDXS's operating margin was −39% last quarter, up 182 points from the same quarter a year ago.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over CDXS on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over CDXS on profitability, with a higher operating margin.
CDXS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$7.8M | +$40K |
| Q2 2026 | -$10.5M | +$9.9M |
| Q1 2026 | -$13.3M | +$1.7M |
| Q4 2025 | $19.6M | +$37.8M |
| Q3 2025 | -$7.9M | +$6.1M |
| Q2 2025 | -$20.5M | -$7.9M |
| Q1 2025 | -$15.1M | -$6.1M |
| Q4 2024 | -$18.2M | -$7.6M |
CDXS has burned cash in almost every quarter: −$12M over the past year, against −$62M the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over CDXS on cash generation, producing positive trailing cash flow while its opponent burns cash.
CDXS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +18% | +16.2M shares |
| 1 year | +19% | +17M shares |
| 3 years | +54% | +37.8M shares |
| 5 years | +58% | +39.5M shares |
| Available history | +90% | +50.7M shares |
CDXS has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
CDXS Net Leverage
CDXS's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
CDXS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 30.5 | Neutral |
| Stochastic | 7.2 | Oversold |
CDXS's weekly RSI is 30 (neutral) and its Stochastic is 7 (oversold).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
CDXS PE vs Healthcare Sector
CDXS has no meaningful PE right now: it lost money over the past year.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
CDXS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.23 | 22% below |
| 20 week MA | $1.52 | 37% below |
| 50 week MA | $1.76 | 45% below |
| 100 week MA | $2.35 | 59% below |
| 200 week MA | $2.79 | 66% below |
CDXS is in a downtrend: it's below all five of its weekly moving averages, and 66% below its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over CDXS on trend strength, trading above more of its moving averages.
CDXS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $17.1 | $22.7 | +33% |
| 2021 | $22.7 | $33.4 | +47% |
| 2022 | $33.4 | $4.43 | -87% |
| 2023 | $4.43 | $3.05 | -31% |
| 2024 | $3.05 | $4.99 | +64% |
| 2025 | $4.99 | $1.63 | -67% |
| 2026 YTD | $1.63 | $0.96 | -41% |
CDXS has finished lower in three of the last six years. It's down 41% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over CDXS on returns for 2026, with the stronger performance.